Filing Flows › Kymera Therapeutics (KYMR) › Q1 2025
Kymera Therapeutics (KYMR) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Kymera Therapeutics (KYMR) reported revenue of $22.1M for the first quarter 2025 (Q1 2025), +115% from a year earlier and +199% from the quarter before. Operating margin was -336.8%, net loss $65.6M (296.7% of revenue).
Kymera Therapeutics, Q1 2025: revenue $22.1M (+115% year over year), operating margin -336.8%, net loss $65.6M, operating cash flow −$79.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.1M | +199% | +115% |
| Operating profit | −$74.4M | — | — |
| Net earnings | −$65.6M | — | — |
| Operating cash flow | −$79.2M | — | — |
What changed
Revenue was $22.1M in Q1 2025, up 115% year over year and up 199% from the previous quarter.
Operating costs exceeded revenue by $74.4M, an operating margin of -336.8%. Total costs grew 42% against revenue growth of 115%. The quarter ended with a net loss of $65.6M, narrower than the previous quarter's $70.8M loss.
Operating cash flow was −$79.2M. Non-cash charges added back $2.0M of depreciation and amortization and $14.2M of share-based compensation. Working capital and other items used $29.9M. Capital expenditures of $467K exceeded it, leaving free cash flow of −$79.6M.
Questions
What was Kymera Therapeutics' revenue in the first quarter 2025?
Kymera Therapeutics (KYMR) reported revenue of $22.1M for the first quarter 2025 (Q1 2025), +115% from a year earlier and +199% from the quarter before.
Was Kymera Therapeutics profitable in the first quarter 2025?
Operating loss was $74.4M (-336.8% of revenue) and net loss $65.6M.